The Role of Magnetic Resonance Imaging in (Future) Cancer Staging

Scheenen, Tom W. J.; Zámecnik, Patrik

doi:10.1097/rli.0000000000000741

Cited by 26 publications

(22 citation statements)

References 57 publications

(52 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In general, the use of imaging parameters to accurately predict the staging of esophageal cancer still requires further study. Furthermore, the application of new techniques may help to improve the efficiency of PET/MRI in predicting T and N staging of esophageal cancer ( 24 – 28 ).…”

Section: Discussionmentioning

confidence: 99%

Value of 18F-FDG PET/MRI in the Preoperative Assessment of Resectable Esophageal Squamous Cell Carcinoma: A Comparison With 18F-FDG PET/CT, MRI, and Contrast-Enhanced CT

Wang

Guo²,

Zhang³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

ObjectivesTo investigate the value of 18F-FDG PET/MRI in the preoperative assessment of esophageal squamous cell carcinoma (ESCC) and compare it with 18F-FDG PET/CT, MRI, and CECT.MethodsThirty-five patients with resectable ESCC were prospectively enrolled and underwent PET/MRI, PET/CT, and CECT before surgery. The primary tumor and regional lymph nodes were assessed by PET/MRI, PET/CT, MRI, and CECT, respectively, and the diagnostic efficiencies were determined with postoperative pathology as a reference standard. The predictive role of imaging and clinical parameters on pathological staging was analyzed.ResultsFor primary tumor staging, the accuracy of PET/MRI, MRI, and CECT was 85.7%, 77.1%, and 51.4%, respectively. For lymph node assessment, the accuracy of PET/MRI, PET/CT, MRI, and CECT was 96.2%, 92.0%, 86.8%, and 86.3%, respectively, and the AUCs were 0.883, 0.745, 0.697, and 0.580, respectively. PET/MRI diagnosed 13, 7, and 6 more stations of lymph node metastases than CECT, MRI, and PET/CT, respectively. There was a significant difference in SUVmax, TLG, and tumor wall thickness between T1-2 and T3 tumors (p = 0.004, 0.024, and < 0.001, respectively). Multivariate analysis showed that thicker tumor wall thickness was a predictor of a higher T stage (p = 0.040, OR = 1.6).Conclusions18F-FDG PET/MRI has advantages over 18F-FDG PET/CT, MRI, and CECT in the preoperative assessment of primary tumors and regional lymph nodes of ESCC. 18F-FDG PET/MRI may be a potential supplement or alternative imaging method for preoperative staging of ESCC.

show abstract

Section: Discussionmentioning

confidence: 99%

Value of 18F-FDG PET/MRI in the Preoperative Assessment of Resectable Esophageal Squamous Cell Carcinoma: A Comparison With 18F-FDG PET/CT, MRI, and Contrast-Enhanced CT

Wang

Guo²,

Zhang³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…This technology allows for the differentiation of malignant and benign lymph nodes according to the contrast-enhanced pattern. Although MRI with USPIO has achieved some success in characterizing small lymph nodes, further research is needed regarding its clinical applicability (55,(69)(70)(71).…”

Section: Discussionmentioning

confidence: 99%

Magnetic Resonance Imaging Evaluation of the Accuracy of Various Lymph Node Staging Criteria in Rectal Cancer: A Systematic Review and Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

BackgroundMagnetic resonance imaging (MRI)-based lymph node staging remains a significant challenge in the treatment of rectal cancer. Pretreatment evaluation of lymph node metastasis guides the formulation of treatment plans. This systematic review aimed to evaluate the diagnostic performance of MRI in lymph node staging using various morphological criteria.MethodsA systematic search of the EMBASE, Medline, and Cochrane databases was performed. Original articles published between 2000 and January 2021 that used MRI for lymph node staging in rectal cancer were eligible. The included studies were assessed using the QUADAS-2 tool. A bivariate random-effects model was used to conduct a meta-analysis of diagnostic test accuracy.ResultsThirty-seven studies were eligible for this meta-analysis. The pooled sensitivity, specificity, and diagnostic odds ratio of preoperative MRI for the lymph node stage were 0.73 (95% confidence interval [CI], 0.68–0.77), 0.74 (95% CI, 0.68–0.80), and 7.85 (95% CI, 5.78–10.66), respectively. Criteria for positive mesorectal lymph node metastasis included (A) a short-axis diameter of 5 mm, (B) morphological standard, including an irregular border and mixed-signal intensity within the lymph node, (C) a short-axis diameter of 5 mm with the morphological standard, (D) a short-axis diameter of 8 mm with the morphological standard, and (E) a short-axis diameter of 10 mm with the morphological standard. The pooled sensitivity/specificity for these criteria were 75%/64%, 81%/67%, 74%/79%, 72%/66%, and 62%/91%, respectively. There was no significant difference among the criteria in sensitivity/specificity. The area under the receiver operating characteristic (ROC) curve values of the fitted summary ROC indicated a diagnostic accuracy rate of 0.75–0.81.ConclusionMRI scans have minimal accuracy as a reference index for pretreatment staging of various lymph node staging criteria in rectal cancer. Multiple types of evidence should be used in clinical decision-making.

show abstract

“…However, due to the accumulation of gadolinium ions in tissues (including the brain), these compounds can be unsafe, especially if they are used repeatedly [ 195 ]. Therefore, the likelihood of using Ferumoxytol and other types of SPIONs as a substitute for gadolinium-containing agents in MRI remains rather high [ 196 – 199 ], even despite reports of possible side effects when using Ferumoxytol as an anti-anemic agent [ 200 ] and, in general, not entirely a clear situation with the degree of toxicity of iron oxide-based MNPs [ 201 ]. Here, apparently, a choice must be made, either to abandon the use of SPIONs altogether due to possible side effects [ 202 ], or still use SPIONs in the MRI method for certain types of tumors, where other types of contrast agents are unacceptable [ 203 , 204 ].…”

Section: Progress In Medical Application Of Magnetic Nanoparticlesmentioning

confidence: 99%

Magnetic Nanoparticles in Medicine: Progress, Problems, and Advances

Koksharov

Губин

Taranov

et al. 2022

J. Commun. Technol. Electron.

View full text Add to dashboard Cite

The review presents an analysis of the current state of research related to the design, development, and practical application of methods for biomedical radioelectronics and nanomedicine, including the use of magnetic nanoparticles. The important role of rational scientific physical approaches and experimental methods in the design of efficient and safe magnetic nanoparticle-based agents for therapy, controlled targeted drug delivery, and diagnostics, including spatial imaging, is emphasized. Examples of successful practical application of magnetic nanoparticles in medicine based on these methods are given, and an analysis of the main problems and prospects of this area of science is conducted.

show abstract

The Role of Magnetic Resonance Imaging in (Future) Cancer Staging

Abstract: Supplemental digital content is available in the text.

Cited by 26 publications

References 57 publications

Value of 18F-FDG PET/MRI in the Preoperative Assessment of Resectable Esophageal Squamous Cell Carcinoma: A Comparison With 18F-FDG PET/CT, MRI, and Contrast-Enhanced CT

Value of 18F-FDG PET/MRI in the Preoperative Assessment of Resectable Esophageal Squamous Cell Carcinoma: A Comparison With 18F-FDG PET/CT, MRI, and Contrast-Enhanced CT

Magnetic Resonance Imaging Evaluation of the Accuracy of Various Lymph Node Staging Criteria in Rectal Cancer: A Systematic Review and Meta-Analysis

Magnetic Nanoparticles in Medicine: Progress, Problems, and Advances

Contact Info

Product

Resources

About